Abstract:Pulmonary fibrosis (PF) is a severe pulmonary disease with limited available therapeutic choices. Recent evidence increasingly points to abnormal lipid metabolism as a critical factor in PF pathogenesis. Our latest research identifies the dysregulation of low-density lipoprotein (LDL) is a new risk factor for PF, contributing to alveolar epithelial and endothelial cell damage, and fibroblast activation. In this study, we first integrative summarize the published literature about lipid metabolite changes found in PF, including phospholipids, glycolipids, steroids, fatty acids, triglycerides, and lipoproteins. We then reanalyze two single-cell RNA-sequencing (scRNA-seq) datasets of PF, and the corresponding lipid metabolomic genes responsible for these lipids' biosynthesis, catabolism, transport, and modification processes are uncovered. Intriguingly, we found that macrophage is the most active cell type in lipid metabolism, with almost all lipid metabolic genes being altered in macrophages of PF. In type 2 alveolar epithelial cells, lipid metabolic differentially expressed genes (DEGs) are primarily associated with the cytidine diphosphate diacylglycerol pathway, cholesterol metabolism, and triglyceride synthesis. Endothelial cells are partly responsible for sphingomyelin, phosphatidylcholine, and phosphatidylethanolamines reprogramming as their metabolic genes are dysregulated in PF. Fibroblasts may contribute to abnormal cholesterol, phosphatidylcholine, and phosphatidylethanolamine metabolism in PF. Therefore, the reprogrammed lipid profiles in PF may be attributed to the aberrant expression of lipid metabolic genes in different cell types. Taken together, these insights underscore the potential of targeting lipid metabolism in developing innovative therapeutic strategies, potentially leading to extended overall survival in individuals affected by PF.

The research advances of leptin in the development of pulmonary fibrosis

Leptin Promotes Pulmonary Fibrosis Development by Inhibiting Autophagy Via PI3K/Akt/mTOR Pathway

Leptin promotes pulmonary fibrosis development by inhibiting autophagy via PI3K/Akt/mTOR pathway.

Research advances on leptin and respiratory diseases]

Research Advances of IL-22 in Development of Pulmonary Fibrosis

High-Fat Diet Related Lung Fibrosis-Epigenetic Regulation Matters

Leptin Promotes the Immune Escape of Lung Cancer by Inducing Proinflammatory Cytokines and Resistance to Apoptosis

Obesity and the Development of Lung Fibrosis

Epigenetic hallmarks in pulmonary fibrosis: New advances and perspectives

Regulation effect of the intestinal flora and intervention strategies targeting the intestinal flora in alleviation of pulmonary fibrosis development

The Mechanism of Leptin on Inhibiting Fibrosis and Promoting Browning of White Fat by Reducing ITGA5 in Mice

Metabolic reprogramming of pulmonary fibrosis

Pulmonary fibrosis: pathogenesis and therapeutic strategies

Signaling molecular regulatory mechanisms of pulmonary fibrosis

Advances in research of inflammatory markers in chronic obstructive pulmonary disease

Effects of leptin deficiency on postnatal lung development in mice

New aspects of the epigenetic regulation of EMT related to pulmonary fibrosis

The novel molecular mechanism of pulmonary fibrosis: insight into lipid metabolism from reanalysis of single-cell RNA-seq databases

Research Progress in Modeling Methods of Rat Lung Fibrosis

High insulin inhibits ferroptosis and alleviates acute lung injury via LNC473-HIF1{alpha}-GPX4/FSP1 axis in obese mice

Therapeutic effects of flavonoids on pulmonary fibrosis: a preclinical meta-analysis